NCT06258980

Use of Recombinant Factor VII as a Prophylactic Therapy for Adolescent Females With Heavy Menstrual Bleeding

Professor and Consultant of Pediatric Hematology Faculty of Medicine, Minia University, Al Minya, Egypt.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 3 (actual)
• Sponsor: Minia University Hospital · Academic / Other
• Sex: Female
• Age: 12 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

the study is conducted on adolescent females proved to be Glanzmanns Thrombaesthenia with heavy menstrual bleeding by the use of 3 doses of recombinant factor VII in the first day of their cycles. bleeding profile and quality of life were assessed before and 1year after this regular recombinant factor VII administration.

Conditions

• Assessing the Bleeding Profile and the Quality of Life of the Enrolled Patients Before and 1 Year After Drug Intervention

Interventions

Type	Name	Description
DRUG	Proph7	Prophylactic recombinant FVII for heavily menorrhagic adolescent Glanzmanns Thrombaesthenia females

Timeline

• Start date: 2023-01-15
• Primary completion: 2024-02-02
• Completion: 2024-02-05
• First posted: 2024-02-14
• Last updated: 2024-02-14

Locations

1 site across 1 country: Egypt

Regulatory

• FDA-regulated drug study